Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 1999-10, Vol.59 (19), p.4906-4911
• Main Authors: KIJIMA, T, OSAKI, T, NISHINO, K, KUMAGAI, T, FUNAKOSHI, T, GOTO, H, TACHIBANA, I, TANIO, Y, KISHIMOTO, T
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - therapy; Adenoviridae; Animals; Antineoplastic agents; Antiviral Agents - therapeutic use; Biological and medical sciences; Carcinoembryonic Antigen - genetics; Cell Line; Colonic Neoplasms - therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); ganciclovir; Ganciclovir - therapeutic use; Genetic Therapy - methods; Genetic Vectors; Herpes simplex virus; Humans; Integrases - genetics; Integrases - metabolism; loxP gene; Male; Medical sciences; Mice; Mice, Nude; neo gene; Pharmacology. Drug treatments; Promoter Regions, Genetic; Simplexvirus - enzymology; Simplexvirus - genetics; Thymidine Kinase - genetics; Thymidine Kinase - metabolism; Transplantation, Heterologous; Tumor Cells, Cultured; Viral Proteins
• ISSN: 0008-5472; 1538-7445

A considerable number of studies of cancer have shown that the cell type-specific promoter is an effective tool for selective expression of foreign genes in tumor cells. However, few reports have demonstrated significant in vivo antitumor effects using this strategy thus far, possibly because the low activity of such a promoter results in insufficient expression of genes in cancer cells as well as in insignificant antitumor effects, even when the cells are infected by highly efficient gene transfer methods. To overcome this problem, we used the Cre/loxP system for the cell type-specific gene therapy against carcinoembryonic antigen (CEA)-producing cancer. We constructed a pair of recombinant Ads. One expresses the Cre recombinase (Cre) gene under the control of the CEA promoter (Ad.CEA-Cre). The other contains the herpes simplex virus thymidine kinase (HSV-TK) gene separated from the strong CAG promoter by insertion of the neomycin resistance (neo) gene (Ad.lox-TK). The HSV-TK gene of the latter Ad is designed to be activated through excisional deletion of the neo gene by Cre enzyme released from the former one only when CEA-producing cells are infected simultaneously with these Ads. Coinfection by these Ads rendered a human CEA-producing cancer cell line 8.4-fold more sensitive to ganciclovir (GCV) compared with infection by Ad.CEA-TK alone, the HSV-TK gene of which is directly regulated by the CEA promoter. On the other hand, coinfection with these Ads did not significantly change the GCV sensitivity of non-CEA-producing cells. Intratumoral injection of Ad.CEA-Cre combined with Ad.lox-TK followed by GCV treatment almost completely eradicated CEA-producing tumors established in the subcutis of athymic mice, whereas intratumoral injection of Ad.CEA-TK with GCV administration at most retarded the growth of inoculated tumors. These results suggest distinct advantages of the Cre/loxP system applied in the conventional cell type-specific gene therapy against cancer.